- Home
- NCLH vs RPRX Comparison
NCLH vs RPRX Comparison
Compare NCLH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- RPRX
- Stock Information
- Founded
- NCLH 1966
- RPRX 1996
- Country
- NCLH United States
- RPRX United States
- Employees
- NCLH N/A
- RPRX N/A
- Industry
- NCLH Marine Transportation
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- NCLH Consumer Discretionary
- RPRX Health Care
- Exchange
- NCLH Nasdaq
- RPRX Nasdaq
- Market Cap
- NCLH 12.1B
- RPRX 11.7B
- IPO Year
- NCLH 2013
- RPRX 2020
- Fundamental
- Price
- NCLH $27.03
- RPRX $30.30
- Analyst Decision
- NCLH Buy
- RPRX Strong Buy
- Analyst Count
- NCLH 16
- RPRX 6
- Target Price
- NCLH $29.27
- RPRX $41.67
- AVG Volume (30 Days)
- NCLH 8.0M
- RPRX 3.8M
- Earning Date
- NCLH 02-25-2025
- RPRX 02-13-2025
- Dividend Yield
- NCLH N/A
- RPRX 2.76%
- EPS Growth
- NCLH N/A
- RPRX 518.56
- EPS
- NCLH 1.25
- RPRX 2.55
- Revenue
- NCLH $9,356,741,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- NCLH $13.11
- RPRX $14.54
- Revenue Next Year
- NCLH $8.08
- RPRX $10.94
- P/E Ratio
- NCLH $21.63
- RPRX $11.88
- Revenue Growth
- NCLH 15.76
- RPRX N/A
- 52 Week Low
- NCLH $14.69
- RPRX $24.05
- 52 Week High
- NCLH $28.64
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- NCLH 58.77
- RPRX 75.65
- Support Level
- NCLH $25.82
- RPRX $29.67
- Resistance Level
- NCLH $26.72
- RPRX $31.09
- Average True Range (ATR)
- NCLH 0.90
- RPRX 0.70
- MACD
- NCLH 0.15
- RPRX 0.51
- Stochastic Oscillator
- NCLH 69.86
- RPRX 86.63
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.